News & Updates

Show Multimedia Only
Is remote insulin pump training safe for youths with T1D? Is remote insulin pump training safe for youths with T1D?

Is remote insulin pump training safe for youths with T1D?

08 Jun 2022

Remote insulin pump training among young patients with type 1 diabetes (T1D) appears to be as safe as in-person training, suggest the results of a recent study.

08 Jun 2022
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

06 Jun 2022